MG-D-1509 / Metagone Biotech - LARVOL DELTA

Camrelizumab Plus Rivoceranib vs Sorafenib in Unresectable Hepatocellular Carcinoma. The reported mOS is the highest reported mOS (22.1m) thus far in the context that mOS for Sorafenib is a lot higher than expected (15.2m)...

Liver cancer, new results for double immunotherapy (breakinglatest.news) - "'The long-term survival data from the Himalaya study are unique in the panorama of advanced hepatocellular carcinoma - says Lorenza Rimassa..."

Media quote

Assessing treatment options for hepatocellular carcinoma (YouTube) - "Lorenza Rimassa, MD...discusses different therapies for hepatocellular carcinoma (HCC)."

Interview • Video

The Synergistic Cytotoxic Effects of GW5074 and Sorafenib by Impacting Mitochondrial Functions in Human Colorectal Cancer Cell Lines. (PubMed, Front Oncol) - "In summary, the C-RAF inhibitor GW5074 might potentiate the cytotoxicity of the B-RAF inhibitor sorafenib mediated through mitochondrial dysfunctions, suggesting that GW5074 potentially serves as a sensitizer for sorafenib application to reduce the risk of drug resistance of CRC treatment. Our findings also provide novel insights on using C-RAF inhibitors combined with sorafenib, the current CRC therapeutic drug choice, in CRC treatment."

Journal • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Metabolic Disorders • Oncology • Solid Tumor • BRAF

Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors. (PubMed, J Clin Med) - "Co-administration therapy of GW5074 and sorafenib demonstrated a favorable safety profile and showed anti-tumor activity in a variety of tumor types. However, the solubility of GW5074 is not satisfactory. A future phase 2a trial will be carried out using the new salted form that has been proven to be more effective."

Journal • P1 data • Hypertension • Oncology • Solid Tumor • CTCs

Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor (clinicaltrials.gov) - P1; N=17; Completed; Sponsor: Metagone Biotech Inc.; Phase classification: P1/2 ➔ P1

Clinical • Phase classification • Oncology • Solid Tumor

Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor (clinicaltrials.gov) - P1/2; N=17; Completed; Sponsor: Metagone Biotech Inc.; Recruiting ➔ Completed; N=33 ➔ 17; Trial completion date: Dec 2019 ➔ Jul 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Oncology • Solid Tumor